Clinical trial
A Multi-center, Multi-dose Phase Ib/IIa Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Impact on Biomarkers of IPG11406 in Patients With Lupus Nephritis
NCT06717815 is registered in ClinicalTrials.gov with Nanjing Immunophage Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Multi-dose Phase Ib/IIa Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Impact on Biomarkers of IPG11406 in Patients With Lupus Nephritis
- Lead sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 25, 2025
- Completion date
- June 8, 2026
- Enrollment
- 24 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.